Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Sunday.
Several other brokerages have also recently weighed in on SGMO. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, November 6th. Guggenheim cut Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 target price on the stock. in a research note on Friday, November 9th. Zacks Investment Research cut Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 18th. JPMorgan Chase & Co. cut Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $35.00 to $11.00 in a research note on Wednesday, November 14th. Finally, Wedbush set a $11.00 target price on Sangamo Therapeutics and gave the company a “hold” rating in a research note on Monday, November 19th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Sangamo Therapeutics presently has an average rating of “Hold” and an average target price of $18.83.
Get Sangamo Therapeutics alerts:
Shares of NASDAQ SGMO opened at $7.72 on Friday. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.07. Sangamo Therapeutics has a 1-year low of $6.26 and a 1-year high of $27.50. The company has a market cap of $848.39 million, a price-to-earnings ratio of -11.03 and a beta of 2.84.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Sangamo Therapeutics had a negative return on equity of 22.06% and a negative net margin of 88.78%. The company had revenue of $23.56 million for the quarter, compared to analysts’ expectations of $26.96 million. During the same period in the previous year, the firm posted ($0.15) earnings per share. The firm’s revenue for the quarter was up 99.5% on a year-over-year basis. As a group, analysts predict that Sangamo Therapeutics will post -0.72 EPS for the current fiscal year.
In other news, VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $12.33, for a total transaction of $61,650.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 25,000 shares of company stock worth $281,500. Insiders own 1.20% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Sangamo Therapeutics by 29.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,787 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 1,552 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $102,000. Merriman Wealth Management LLC bought a new position in Sangamo Therapeutics in the fourth quarter worth approximately $119,000. Cambridge Investment Research Advisors Inc. bought a new position in Sangamo Therapeutics in the third quarter worth approximately $182,000. Finally, Virtu Financial LLC bought a new position in Sangamo Therapeutics in the fourth quarter worth approximately $129,000. 62.90% of the stock is currently owned by hedge funds and other institutional investors.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Read More: Leveraged Buyout (LBO) Explained
To view ValuEngine’s full report, visit ValuEngine’s official website.